Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
COVID-19 Antibody Cocktail Given to 13,000 in Japan by August-End: MHLW
Chugai Pharmaceutical’s COVID-19 antibody cocktail Ronapreve (casirivimab + imdevimab) has been administered to an estimated 13,000 patients in Japan at roughly 1,700 facilities as of the end of August, the Japanese health ministry said on September 9. Ronapreve earned special…
To read the full story
Related Article
- Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
- Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
- Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
- Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
- Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
- LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…